Nepafenac Catalog No.:M7815-10 Structural mechanisms determining inhibition of

Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors

CP-456773 inhibits interleukin 1β (IL-1β) secretion and caspase 1 processing

is a potent and long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes

Formula: C27H32N8O2

with antifibrotic and potential antineoplastic activities

Nepafenac Catalog No.:M7815-10 Structural mechanisms determining inhibition ofNepafenac is a non steroidal anti inflammatory drug (NSAID), usually sold as a prescription eye drop (0. 1% solution. Nepafenac is manufactured by Alcon as Nevanac. It is used to treat pain and inflammation associated with cataract surgery. The usual dose is 1 drop in each affected eye beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. Its side effects may include